Comparing the current results to its competitors, Sage Therapeutics Inc reported Revenue increase in the 2 quarter 2025 by 265.84 % year on year. The sales growth was above Sage Therapeutics Inc 's competitors' average revenue growth of 12.35 %, achieved in the same quarter.
Sage Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 4082.52 %
January 11, 2025
Sage Therapeutics: Striking Acquisition Interest Amidst Unprecedented Revenue Surge In a significant development within the biopharmaceutical sector, Sage Therapeutics, Inc. confirmed it has received an unsolicited, nonbinding proposal from Biogen Inc. to acquire the company for $7.22 per share. This proposal, aimed at acquiring all outstanding shares of Sage not already owned by Biogen, has prompted the Sage Board of Directors to assess the offer in accordance with its fiduciary responsibilities, guided by the advice of independent financial and legal experts. This unsolicited approach from Biogen comes at a notable time for Sage Therapeutics, which recently reported an extraordinary increase in revenue for...
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Bioxytran Inc's business model revolves around developing and commercializing innovative therapeutic solutions, specifically focusing on oxygen therapeutics for various medical applications.
Sources:
Sage Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sage Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
